Defence Therapeutics’ proprietary Accum technology platform reduces the half-maximal inhibitory concentration (IC50) of antibody–drug conjugates up to fifty-fold by solving the endosome-entrapment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback